Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash from Investing Activities: 2013-2025

Historic Cash from Investing Activities for Ocular Therapeutix (OCUL) over the last 12 years, with Sep 2025 value amounting to -$6.0 million.

  • Ocular Therapeutix's Cash from Investing Activities fell 6633.71% to -$6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.2 million, marking a year-over-year decrease of 498.25%. This contributed to the annual value of -$1.3 million for FY2024, which is 78.84% up from last year.
  • Per Ocular Therapeutix's latest filing, its Cash from Investing Activities stood at -$6.0 million for Q3 2025, which was down 437.49% from -$1.1 million recorded in Q2 2025.
  • Over the past 5 years, Ocular Therapeutix's Cash from Investing Activities peaked at -$89,000 during Q3 2024, and registered a low of -$6.0 million during Q3 2025.
  • In the last 3 years, Ocular Therapeutix's Cash from Investing Activities had a median value of -$742,000 in 2024 and averaged -$1.5 million.
  • In the last 5 years, Ocular Therapeutix's Cash from Investing Activities soared by 92.45% in 2024 and then slumped by 6,633.71% in 2025.
  • Ocular Therapeutix's Cash from Investing Activities (Quarterly) stood at -$631,000 in 2021, then tumbled by 240.73% to -$2.1 million in 2022, then soared by 78.65% to -$459,000 in 2023, then surged by 55.99% to -$202,000 in 2024, then plummeted by 6,633.71% to -$6.0 million in 2025.
  • Its Cash from Investing Activities was -$6.0 million in Q3 2025, compared to -$1.1 million in Q2 2025 and -$1.9 million in Q1 2025.